NCT03505554View on ClinicalTrials.gov

A Study of Oral Lorlatinib in Patients With Relapsed ALK Positive Lymphoma

PHASE2UnknownINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

October 10, 2017

Primary Completion Date

December 31, 2024

Study Completion Date

December 31, 2024

Conditions
Anaplastic Large Cell Lymphoma, ALK-Positive
Interventions
DRUG

Lorlatinib

100 mg QD

Trial Locations (2)

20900

RECRUITING

Asst-Monza, Monza

Unknown

RECRUITING

UOC Ematologia, Ospedale S. Eugenio, Roma

Sponsors

Collaborators (1)

Pfizer
All Listed Sponsors
collaborator

Pfizer

INDUSTRY

lead

University of Milano Bicocca

OTHER

NCT03505554 - A Study of Oral Lorlatinib in Patients With Relapsed ALK Positive Lymphoma | Biotech Hunter | Biotech Hunter